Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Acquired resistance to cancer immunotherapy.

Literature DB >> 29968044

Acquired resistance to cancer immunotherapy.

Arianna Draghi¹, Christopher Aled Chamberlain¹, Andrew Furness², Marco Donia^3,4.

Abstract

In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms.

Entities: Disease Species

Keywords: Acquired resistance; Cancer immunotherapy; Checkpoint inhibitors; Immune escape; Immune evasion

Mesh：

Substances：

Year: 2018 PMID： 29968044 DOI： 10.1007/s00281-018-0692-y

Source DB: PubMed Journal: Semin Immunopathol ISSN： 1863-2297 Impact factor: 9.623

96 in total

Review 1. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors: Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal: Cell Date: 2017-02-09 Impact factor: 41.582

Review 2. Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors: Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal: Cancer Cell Date: 2015-04-06 Impact factor: 31.743

3. Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors: Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal: N Engl J Med Date: 2014-11-19 Impact factor: 91.245

4. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Authors: Scott Gettinger; Jungmin Choi; Katherine Hastings; Anna Truini; Ila Datar; Ryan Sowell; Anna Wurtz; Weilai Dong; Guoping Cai; Mary Ann Melnick; Victor Y Du; Joseph Schlessinger; Sarah B Goldberg; Anne Chiang; Miguel F Sanmamed; Ignacio Melero; Jackeline Agorreta; Luis M Montuenga; Richard Lifton; Soldano Ferrone; Paula Kavathas; David L Rimm; Susan M Kaech; Kurt Schalper; Roy S Herbst; Katerina Politi
Journal: Cancer Discov Date: 2017-10-12 Impact factor: 39.397

5. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Authors: Nadeem Riaz; Jonathan J Havel; Vladimir Makarov; Alexis Desrichard; Walter J Urba; Jennifer S Sims; F Stephen Hodi; Salvador Martín-Algarra; Rajarsi Mandal; William H Sharfman; Shailender Bhatia; Wen-Jen Hwu; Thomas F Gajewski; Craig L Slingluff; Diego Chowell; Sviatoslav M Kendall; Han Chang; Rachna Shah; Fengshen Kuo; Luc G T Morris; John-William Sidhom; Jonathan P Schneck; Christine E Horak; Nils Weinhold; Timothy A Chan
Journal: Cell Date: 2017-10-12 Impact factor: 41.582

6. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal: Science Date: 2015-03-12 Impact factor: 47.728

7. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245

Review 8. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.

Authors: Jonathan M Pitt; Marie Vétizou; Romain Daillère; María Paula Roberti; Takahiro Yamazaki; Bertrand Routy; Patricia Lepage; Ivo Gomperts Boneca; Mathias Chamaillard; Guido Kroemer; Laurence Zitvogel
Journal: Immunity Date: 2016-06-21 Impact factor: 31.745

9. PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.

Authors: Nisha Nagarsheth; Dongjun Peng; Ilona Kryczek; Ke Wu; Wei Li; Ende Zhao; Lili Zhao; Shuang Wei; Timothy Frankel; Linda Vatan; Wojciech Szeliga; Yali Dou; Scott Owens; Victor Marquez; Kaixiong Tao; Emina Huang; Guobin Wang; Weiping Zou
Journal: Cancer Res Date: 2015-11-13 Impact factor: 12.701

Acquired resistance to cancer immunotherapy.

Review 1. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Review 2. Immune checkpoint blockade: a common denominator approach to cancer therapy.

3. Genetic basis for clinical response to CTLA-4 blockade in melanoma.

4. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

5. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

6. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

7. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Review 8. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.

9. PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.

10. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

1. Anti-cancer immunotherapy: breakthroughs and future strategies.

Review 2. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.

Review 3. The significance of PAK4 in signaling and clinicopathology: A review.

Review 4. Potential of Black Phosphorus in Immune-Based Therapeutic Strategies.

Review 5. Current Perspectives in Cancer Immunotherapy.

6. Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma.

Review 7. Nanomedicines for Overcoming Cancer Drug Resistance.

Review 8. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?